Last reviewed · How we verify
Malaria — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Krintafel | TAFENOQUINE | 60 Degrees Pharms | tafenoquine | 2018-01-01 | ||
| Quinidine Gluconate | QUINIDINE SULFATE | Eli Lilly | Antiarrhythmic | Muscarinic acetylcholine receptor M2 | 1950-01-01 | |
| Alaxin | ARTENIMOL | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A | artenimol | |||
| Dihydroartemisinin | Dihydroartemisinin | Shanghai Zhongshan Hospital |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- 60 Degrees Pharms · 1 drug in Malaria
- Eli Lilly · 1 drug in Malaria
- Shanghai Zhongshan Hospital · 1 drug in Malaria
- Sigma-Tau Industrie Farmaceutiche Riunite S.p.A · 1 drug in Malaria
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Malaria:
Cite this brief
Drug Landscape (2026). Malaria — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/malaria. Accessed 2026-06-10.
Related
- Malaria full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing